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Mucolipidosis type IV (MLIV) is an autosomal recessive lysosomal storage disorder often
characterized by severe neurodevelopmental abnormalities and neuro-retinal degeneration.
Mutations in the TRPML1 gene are causative for MLIV. We used lead optimization strategies
to identify—and MLIV patient fibroblasts to test—small-molecule activators for their potential
to restore TRPML1 mutant channel function. Using the whole-lysosome planar patch-clamp
technique, we found that activation of MLIV mutant isoforms by the endogenous ligand
PI(3,5)P2 is strongly reduced, while activity can be increased using synthetic ligands. We also
found that the F465L mutation renders TRPML1 pH insensitive, while F408D impacts
synthetic ligand binding. Trafficking defects and accumulation of zinc in lysosomes of MLIV
mutant fibroblasts can be rescued by the small molecule treatment. Collectively, our data
demonstrate that small molecules can be used to restore channel function and rescue disease
associated abnormalities in patient cells expressing specific MLIV point mutations.
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M
ucolipidosis type IV (MLIV) has been described for the
first time in the 1970s (ref. 1). It is an autosomal
recessive lysosomal storage disorder often characterized
by severe neurodevelopmental abnormalities, neuro-retinal
degeneration and other ophthalmologic signs such as corneal
opacity and strabismus. Most patients are unable to speak or walk
independently. Storage bodies of lipids and water-soluble
substances are seen by electron microscopy in almost every cell
type of the patients. Constitutive achlorhydria associated with a
secondary elevation of serum gastrin levels is also a characteristic
feature of the disease. Iron deficiency anaemia, secondary to the
achlorhydria, is another phenotypic feature which occurs in about
50% of the patients2–5.
Eventually, mutations in the TRPML1 (MCOLN1) gene were
discovered as the genetic cause of MLIV6–8. In recent years,
TRPML1 has been characterized using electrophysiological tools
and its basic cation channel properties have been investigated9–19,
its protein–protein interaction network has been explored20–24,
and knockout mouse models have been generated and
investigated25–28. However, effective treatment options for
MLIV patients are still missing. Unfortunately, many patients
carry mutations that introduce premature stop signals in the
TRPML1 gene6–8. As a result, the TRPML1 protein is completely
absent, or abnormally short and lacks the ion conducting pore
between TMD5 and TMD6. Some patients however carry single
point mutations which do not destroy the open reading
frame3,7,29–32. While some of these appear to be largely
mislocalized, others retain a predominant lysosomal
localization. Mutant isoforms that remain or partially remain
correctly localized but may be largely inactive on stimulation with
endogenous ligands appeared to be good candidates for a small
molecule therapeutic approach.
An impressive example for such a strategy is the cystic fibrosis
transmembrane conductance regulator (CFTR) channel. Here,
small-molecule synthetic ligands have recently been developed,
which are able to correct the defective gating of, for example,
DF508-CFTR33,34.
Encouraged by this precedent, we set out for a systematic
investigation of small-molecule ligand effects on TRPML1 wild-
type- (WT) and mutant-expressing patient fibroblasts. In a
translational approach, we studied the potential of these synthetic
small-molecule ligands to rescue endogenous channel activity as
well as endolysosomal trafficking defects and accumulation of
heavy metals (zinc), which may ultimately lead to the observed
disease phenotype. Furthermore, by studying the small–molecule-
mediated activation of MLIV mutant isoforms such as F465L and
F408D, we provide novel mechanistic insights into the pH
regulation of TRPML1 and synthetic ligand binding.
Results
Subcellular localization of MLIV causing TRPML1 mutants. To
analyse the subcellular localization of TRPML1 mutant channels,
YFP-tagged hTRPML1 WT and mutant channels were expressed
in murine embryonic fibroblasts and colocalization of channel
proteins with lysosomes was visualized using LysoTracker Deep
Red. We focused on several MLIV causing point mutants
described in the literature with either unknown subcellular
localization (R403C, Y436C, V446L, V447P, S456L)3,7,29,31,32, or
mutant isoforms reported to show partial localization on
endosomes and lysosomes, that is, F408D, an in-frame mutant
that lacks one amino acid, and F465L7,30 (Fig. 1a,b;
Supplementary Table 1; Supplementary Fig. 1). We confirmed
substantial colocalization of LysoTracker with TRPML1-YFP
WT. We further found that F408D, Y436C and F465L show
substantial colocalization with LysoTracker (Fig. 1a). R403C,
V446L, V447P and S456L did colocalize to a much lesser extent
with LysoTracker compared with WT and rather showed an
expression pattern similar to L106P or D362Y, reported
previously to colocalize with the ER35,36. To quantify the
relative degree of colocalization between LysoTracker and
TRPML1 or the MLIV mutants, we calculated the respective
Pearson Correlation Coefficients (Fig. 1c).
SF-22 increases channel activity of TRPML1 mutant isoforms.
We have previously reported that a plasma membrane variant
(PM variant) of WT hTRPML1 (TRPML1DNC) can be activated
by SF-22 (5-chloro-N-(2-piperidin-1-ylphenyl)thiophene-2-sul-
phonamide) in calcium imaging experiments15. Here, we applied
the whole-lysosome planar patch-clamp technique37,38 to
investigate the small-molecule activation of WT hTRPML1 and
selected mutant isoforms of TRPML1. We demonstrate that SF-
22 elicits inwardly rectifying (from lysosomal lumen to cytosol)
currents in lysosomes isolated from a HEK293 cell line stably
expressing hTRPML1 (Fig. 2a). We further show that PI(3,5)P2,
which has been reported recently to activate TRPML channels14,
has a comparable effect on TRPML1 channel activity as SF-22
when applied at a concentration of 10 mM, respectively (Fig. 2b).
Both, SF-22 and PI(3,5)P2 evoked currents were reduced when
luminal pH was increased as reported previously (Fig. 2a,b; SF-22:
 43.1±3.9 pA (n¼ 3; pH 7.2) versus  107.4±10.6 pA (n¼ 9;
pH 4.6) at  200 mV; PI(3,5)P2:  28±2 pA (n¼ 4; pH 7.2)
versus  101.7±9.2 pA (n¼ 7; pH 4.6) at  200 mV) (refs 9,16).
We further show that the observed effects are independent of the
compound applied to increase the size of the lysosomes before
isolation and patch-clamp experimentation. Both, treatment with
vacuolin or the PIKfyve inhibitor YM-201636 showed similar
results (Supplementary Fig. 2).
When PI(3,5)P2 was applied on lysosomes overexpressing
the mutant isoforms F408D, Y436C or F465L, we found that
its effect on channel activity was much smaller compared with
WT. Surprisingly, SF-22 evoked channel activity in F408D and
F465L lysosomes was three to fourfold higher compared with
PI(3,5)P2 (Fig. 2c,d,h). Dose–response measurements with
PI(3,5)P2 revealed a strong decrease in efficacy for both F408D
and F465L compared with WT, while EC50 values (relative
potency) were comparable (0.17±0.01 mM for WT TRPML1,
0.27±0.14 mM for F465L and 0.1±0.03 mM for F408D) (Fig. 2e).
Dose–response measurements with SF-22 revealed an EC50 of
0.51±0.05 mM for WT TRPML1, 0.64±0.17 mM for F465L and
1.41±0.36 mM for F408D. While F408D showed a significant shift
in the dose–response curve affecting potency, the relative efficacy
of SF-22 was similar in F408D compared with WT. In contrast,
it was decreased in F465L (Fig. 2f,g).
No significant channel activation could be detected with SF-22
on lysosomes expressing the Y436C mutant although Y436C was
present in LysoTracker positive vesicles in intact cells as well as in
enlarged isolated lysosomes (Figs 1b and 2h).
Further development of the lead structure SF-22. With the aim
to further improve the efficacy and potency profile of SF-22, we
generated several series of chemically modified SF-22 analogues
(Fig. 3a and Supplementary Figs 3 and 4) and analysed them
using single-cell calcium imaging and the PM variant of TRPML1
(TRPML1(NC))15 (Fig. 3b; Supplementary Fig. 3). Systematic
modifications were performed in any structural motif of the lead
structure (phenyl ring, thiophene, piperidine and sulphonamide;
n¼ 40 compounds/modifications total) (Fig. 3a).
In calcium imaging experiments, we found that modifying
the thiophene rest in SF-22 by replacing chlorine with a methyl
group (MK6-83) greatly increased compound efficacy for
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TRPML1 while other modifications were not beneficial (Fig. 3b;
Supplementary Fig. 3). In lysosomal planar patch-clamp experi-
ments we confirmed that, compared with SF-22, MK6-83 showed
an increased efficacy in activating TRPML1 WT and F408D in
isolated lysosomes. Efficacy remained unaltered in F465L
lysosomes (Fig. 3c–e). Likewise, unaltered efficacy was seen in
Y436C-expressing lysosomes (Fig. 3c–e). Next, we performed
dose–response measurements that revealed an EC50 of
0.11±0.01 mM for WT TRPML1 and 0.1±0.03 mM for F465L
when activated with MK6-83 (Fig. 3e) compared with
0.51±0.05 mM for WT TRPML1 and 0.64±0.17 mM for F465L
when activated with SF-22 (Fig. 2f). Thus, compound MK6-83
showed improved potency in WT and F465L lysosomes, while
potency was not significantly shifted in F408D lysosomes
(1.23±0.19 mM versus 1.41±0.36 mM for SF-22) (Fig. 3e).
We further found that F465L is insensitive to pH changes when
activated with SF-22 or MK6-83 (pH 4.6 luminal versus pH 7.2
luminal), while F408D shows similar pH sensitivity as WT
TRPML1 (Fig. 4a–c). The effects of synthetic and endogenous
ligands (SF-22 and PI(3,5)P2) were additive, suggesting different
binding sites and independent gating mechanisms, while the
effects of the two structurally related sythetic ligands SF-22 and
MK6-83 were not additive, most likely due to competition for the
same binding site (Fig. 4d–h).
To test for cell viability, we performed MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) tests39.
We used plumbagin (5-hydroxy-2-methyl-1,4-naphthoquinone)
and the protein kinase inhibitor staurosporine as positive controls
to demonstrate cell toxicity and found that concentrations of
MK6-83 and SF-22 ranging from 0.2 to 30 mM showed no signs of
cytotoxicity (Supplementary Fig. 5).
In summary, the above-described chemical modifications led to
a new candidate activator of TRPML1 with an improved efficacy
and potency profile: MK6-83.
Effect of SF-22 and MK6-83 on MLIV patient-derived cells. To
test for in vivo effects of the TRPML1-activating compounds, we
persued a translational approach. We used lysosomes isolated
from fibroblast cell lines derived from MLIV patients carrying
either the F408D, the R403C or the V446L mutation. Human
TRPML1þ /þ (GM03440) and TRPML1 / (GM02048) fibro-
blast cell lines were used as positive and negative control,
respectively. In line with the above-described results for over-
expressing HEK293 cells, we found that lysosomes isolated from
TRPML1þ /þ fibroblasts (WT) were activated by SF-22 and
MK6-83. As further expected, MK6-83 showed greater efficacy
than SF-22 (Fig. 5a,f,g). Lysosomes isolated from F408D expres-
sing cells showed activation similar to WT for both compounds
(Fig. 5b,f,g). In contrast, SF-22 and MK6-83 had no significant
effect on lysosomes isolated from TRPML1 / fibroblasts




















































































Figure 1 | Subcellular localization of MLIV causing point mutants of TRPML1. (a) Representative images of WT and selected MLIV causing mutant
isoforms of human TRPML1 overexpressed in WT fibroblasts. Depicted mutants show predominant endolysosomal localization. All WT and mutant
variants were cloned with YFP in fusion at the C terminus. Cells were transfected for 24–48 h and incubated with LysoTracker Deep Red (100 nM) for
30 min at 37 C before confocal analysis. Scale bar, 20mm. (b) Cartoon of the human TRPML1 protein illustrating the estimated positions of known MLIV
causing TRPML1 point mutations in exon regions. (c) Pearson Correlation Coefficients (PCC) to quantify the colocalization of TRPML1 WT and mutant
isoforms with LysoTracker Deep Red. Shown are mean PCC values±s.e.m. of at least 10 cells, each; **Po0.01, *Po0.05. Statistical significance was
determined via one-way analysis of variance followed by Tukey’s post test.
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Figure 2 | Effect of small-molecule activators and PI(3,5)P2 on activation of TRPML1 WT and mutant channel isoforms overexpressed in HEK293 cells.
(a,b) Current–voltage relations of whole-lysosome planar patch-clamp experiments demonstrating that human TRPML1-YFP is activated by SF-22 (10mM)
(a) and PI(3,5)P2 (diC8, 10mM) (b) in a pH-dependent manner; NT, non-transfected control cells (c,d) Current–voltage relations of whole-lysosome planar
patch-clamp experiments demonstrating that the effect of PI(3,5)P2 on the channel activity of MLIV causing TRPML1 mutant isoforms F408Dor F465L
is three to fourfold smaller than the effect of SF-22. (e,f) Dose–response curves showing effects of SF-22 and PI(3,5)P2 on mutant and WT TRPML1
expressing lysosomes. (g) Bar diagram summarizing data at  200 mV from experiments shown in a–d. ***Po0.001, **Po0.01; n¼ number of
experiments. (h) Fluorescence images of enlarged lysosomes isolated from TRPML1 mutant and WT-expressing HEK293 cells after vacuolin treatment.
Scale bar, 5 mm.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms5681
4 NATURE COMMUNICATIONS | 5:4681 | DOI: 10.1038/ncomms5681 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
cells showed only little activation by SF-22 and MK6-83.
Nevertheless, MK6-83 appeared to be significantly more
efficacious on fibroblast lysosomes isolated from R403C or V446L
expressing cells than on those isolated from TRPML1 / cells
(Fig. 5d,e,g).
MK6-83 effects on trafficking and lysosomal zinc buildup.
Lactosylceramide has been used before to demonstrate abberrant
trafficking in MLIV fibroblasts40–43. In the present study, we used
BODIPY FL C5-LacCer and examined its distribution in WT and
MLIV fibroblasts in pulse-chase experiments. In MLIV cells, a
strong punctate pattern of LacCer was observed across the cell
soma, while in WT cells a predominant perinuclear pattern of
LacCer was found with little labelling of cytoplasmic vesicles as
described previously40,41 (Fig. 6a). Like TRPML1 / , F408D
mutant-expressing fibroblasts presented with prominent labelling
of cytoplasmic vesicles (Fig. 6a). Treatment with MK6-83 but not



















































































Figure 3 | Screening for novel SF-22 analogues and effect of SF-22 and MK6-83 on TRPML1 channel activity in WT- and mutant isoform-expressing
lysosomes. (a) Shown are the main strategies of chemical modifications of SF-22 and the chemical structure of the novel lead compound MK6-83.
For further details, refer to Supplementary Methods section and Supplementary Figs 3 and 4. (b) Shown are representative calcium imaging measurements
of HEK293 cells transiently transfected with the PM variant TRPML1(NC)-YFP and loaded with fura-2 (mean values±s.e.m. of at least 10 cells, each).
(c) Current–voltage relations of whole-lysosome planar patch-clamp experiments demonstrating activation of hTRPML1 and MLIV causing mutant
isoforms by MK6-83 (10 mM). (d) Bar diagram summarizing data at  200 mV from experiments shown in a in comparison to SF-22 effects.
(e) Dose–response curves showing potency of MK6-83 on TRPML1 WT- and mutant isoform-expressing lysosomes.
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efficient rescue of the trafficking defects in F408D mutant
channel-expressing cells. In contrast, no effect was found on
TRPML1 / cells (Fig. 6a,b).
Different groups have previously reported that zinc accumu-
lates in lysosomes in MLIV fibroblasts or after knockdown of
TRPML144,45. Heavy metal accumulation may ultimately lead to
the neurodegenerative effects seen in MLIV patients. We used
MLIV fibroblasts to verify these findings and to examine a
possible rescue effect of MK6-83 on lysosomal zinc accumulation.
We found that LysoTracker positive compartments of
TRPML1 / fibroblasts displayed strong vesicular FluoZin-3
fluorescence when pretreated with ZnCl2 as described
previously45,46. The zinc accumulation in TRPML1 /























































































































































Figure 4 | Regulation of TRPML1 mutant isoforms by pH and additive effect between endogenous and synthetic TRPML1 ligands. (a) Similar to the
WT channel activity of TRPML1 mutant isoform F408D is enhanced by low pH. (b) Lack of effect of low pH on F465L. (c) Bar diagram summarizing
data at  200 mV from experiments shown in a,b. (d,e) Additive effect of PI(3,5)P2 and SF-22 on WT TRPML1 currents in lysosomes (d) and respective
time course of current shown in d (e). (f,g) Lack of additive effect after co-application of SF-22 and MK6-83 (f) and respective time course of
current shown in f (g). (h) Bar diagram summarizing data from experiments shown in d,g. ***Po0.001, **Po0.01; n¼ number of experiments.
Data are presented as mean±s.e.m.
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In contrast, zinc accumulation in F408D mutant-expressing cells
was significantly ameliorated by MK6-83 (Fig. 6c,d). Not only the
number but also the size of FluoZin-3 positive structures was
markedly reduced and comparable to WT.
Discussion
In the present study, we developed a novel small-molecule agonist
of TRPML1, termed MK6-83. Using this agonist, we demonstrate
that the effect of specific MLIV causing mutations on TRPML1
channel activity and its functions in endolysosomal trafficking
and heavy metal homeostasis can be restored. While the synthetic
ligand strongly activates WT and the mutant isoforms F408D and
F465L, channel activation by its endogenous ligand PI(3,5)P2 is
remarkably reduced in these mutants. F408 resides at the lower
end of TMD4 or shortly after TMD4, depending on the applied
prediction programme. F465 is part of the highly conserved pore
helix region. The obtained potency data suggest that loss of
phenylalanine at position F408 has an effect on the binding
affinity of small molecule ligands of the SF-22 type, while the
change in efficacy in case of F465L points to a change in the
ability of the compound to produce the same maximal response
as in the WT isoform, possibly due to severe alterations in the
pore region of the channel. Notably, we found that F465L has lost
its pH sensitivity. Loss of phenylalanine at position 465 abrogates
the proton-mediated increase in channel activity observed in WT
TRPML1. We thus provide novel mechanisitic insights into the
pH regulation of TRPML1. Critical sites for pH regulation have
been found in other TRP channels to reside in the pore region, for
example, in case of TRPV1 (refs 47,48). For example, amino acid
F660 has recently been identified as essential for the proton-
mediated gating of TRPV1 (ref. 48).
Interestingly, none of the test compounds could evoke
significant channel activation in Y436C-expressing lysosomes
although Y436C, just like F408D and F465L, appears to still
largely reside in lysosomes (Fig. 1a). Y436C is located in the
centre of TMD5 of TRPML1. TMD5 mutations in TRPML
channels have recently been shown to have a critical impact on
TRPML channel opening (varitint-waddler mutant isoforms and
analogues). Thus, mutation of V432 to proline renders TRPML1
constitutively active10,13. Likewise, C430P and C431P mutants
were found to be constitutively active. In contrast, V436P
rendered the channel completely inactive13. Similarly, V436C
may render the channel inactive by a mechanism which cannot be
overcome by compounds of the SF-22 type.
Most importantly, in a translational approach, we found that
the small-molecule agonists of TRPML1 have the ability to restore
channel activity in lysosomes isolated from MLIV patient
fibroblasts and to improve defects in endolysosomal trafficking
(LacCer) as well as heavy metal ion homeostasis (lysosomal zinc
accumulation) observed in MLIV mutant cells. While MK6-83
had a significant rescue effect on F408D mutant-expressing
fibroblasts, LacCer trafficking could not be rescued in cells
completely lacking expression of TRPML1 (TRPML1 / ).
Similar to the LacCer trafficking defect, we found that zinc
accumulation in TRPML1 / fibroblasts was not reversible on
treatment with MK6-83. In contrast, zinc accumulation in F408D
mutant-expressing cells was strongly reduced by MK6-83.
In summary, the results suggest that the novel TRPML1
activator MK6-83 may be used as a potential pharmacological
treatment option for a specific subgroup of MLIV patients.
Methods
Compounds and chemical syntheses. Compounds SF-22 (ref. 15) and
Z133963852 (5-chloro-N-methyl-N-{[2-(piperidin-1-yl)phenyl]methyl}
thiophene-2-sulphonamide) were purchased through MolPort (MolPort, Latvia):
MolPort-004-039-979 (SF-22) and MolPort-009-399-330 (Z133963852). Stock
solutions of 10 mM in DMSO were prepared for each compound. All other
compounds were synthesized de novo as described in the Supplementary Methods
section. Briefly, the sulphonamides were obtained from the amine building blocks
(ring-substituted anilines, aminopyridines, cyclohexylamines, benzylamines) and
appropriate thiophene (or furan) sulfonyl chlorides. The thiophenecarboxamides
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Figure 5 | SF-22 and MK6-83 evoked currents in human patient fibroblasts. (a–e) Representative currents elicited in lysosomes isolated from
human fibroblast cells derived from healthy individuals (a) Individuals with MLIV causing mutations in TRPML1 resulting in the complete loss of TRPML1
protein (TRPML1 / ) (b) or individuals with MLIV causing point mutations in TRPML1: V446L (c) F408D (d) and R403C (e). (f) Bar diagram
summarizing data at  200 mV from experiments shown in a–c. Recordings shown were obtained with 10mM SF-22 and 10mM MK6-83, respectively.
(g) Dot plot summarizing data at  200 mV from experiments shown in a–e. Recordings shown were obtained with 10mM MK6-83, respectively.
***Po0.001, **Po0.01, *Po0.05; n¼ number of experiments. Data are presented as mean±s.e.m.
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chlorides. The thienyl sulphones were obtained by alkylation of sodium sulfinates
(prepared by reduction of sulfonyl chlorides) with an appropriate benzyl chloride.
cDNA constructs, cell culture and transfection. Human WT TRPML1 was
subcloned into pcDNA3 expression vector (Invitrogen Life Technologies, Breda,
The Netherlands) as described before15. All point mutations were generated by
standard QuikChange site-directed mutagenesis according to the manufacturer’s
guidelines (Agilent Technologies Inc., USA).
HEK293 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), 100 U penicillin per ml and
100mg streptomycin per ml. HEK293 cells were transiently transfected with Fugene
(Roche) or GeneExpresso Max Transfection Reagent (Excellgen) according to the
manufacturer’s protocols and used for LSM experiments 24–48 h after transfection.
Murine embryonic fibroblasts were maintained in DMEM supplemented
with 10% FBS, 100 U penicillin per ml and 100 mg streptomycin per ml. Cells
were transiently transfected with TurboFect (Fermentas) according to the
manufacturer’s protocol and used for further processing 24–48 h after transfection.
Human skin fibroblast cells from a MLIV patient (TRPML1 / , clone GM02048)
and a WT control (TRPML1þ /þ , clone GM03440) were obtained from the Coriell
Institute for Medical Research (NJ, USA). Other human fibroblast cell lines were
provided by Dr Schiffmann (Institute of Metabolic Disease, Baylor Research
Institute, Dallas, TX, USA). All human material was obtained and worked with in
compliance with ethical regulations.
Planar patch-clamp electrophysiology and calcium imaging. Whole-lysosome
planar patch-clamp recordings and preparation of lysosomes (HEK293, Human
Fibroblast) were performed as described previously37,38. In brief, late endosomes
and lysosomes were enlarged by treating the cells with 1 mM vacuolin-1
overnight12,37,38,49. The following day, cells were homogenized in homogenization
buffer (0.25 M sucrose, 10 mM Tris-Cl, pH 7.4) on ice using a potter homogenizer
to obtain whole-cell lysates. The lysates were centrifuged at 14,000 g for 15 min at
4 C. The supernatant was treated with 8 mM CaCl2 (final concentration) on ice for
5 min, followed by a second centrifugation step at 25,000 g for 15 min at 4 C. The
supernatant was collected and the pellet washed in 150 mM KCl, 10 mM Tris-Cl,
pH 7.4, followed by a final centrifugation step at 25,000 g for 15 min at 4 C. The
planar patch-clamp technology combined with a pressure control system and
microstructured glass chips containing an aperture of B1 mm diameter (resistances
of 10–15 MO) (Port-a-Patch, Nanion Technologies) were applied as described37,38.
Currents were recorded using an EPC-10 patch-clamp amplifier and PatchMaster
acquisition software (HEKA). Data were digitized at 40 kHz and filtered at 2.8 kHz.
Cytoplasmic solution contained (in mM) 60 KF, 70 K-MSA (methanesulfonate),
0.2 Ca-MSA, 10 HEPES (pH adjusted with KOH to 7.2). Luminal solution was 60
Ca-MSA, 70 K-MSA, 10 HEPES (pH adjusted with MSA to 4.6). The membrane
potential was held at þ 60 mV, and 500 ms voltage ramps from  200 to
þ 100 mV were applied every 5 s. Due to high luminal calcium used to ensure giga
seals when performing whole-endolysosomal patch-clamp on the port-a-patch
system37,38, the inward currents are less rectifying and reverse at more positive
potentials, depending on current amplitude and protein expression level9. All
recordings were obtained at room temperature and were analysed using
PatchMaster (HEKA) and Origin 6.1 (OriginLab) software. Liquid junction
potential was corrected. Water-soluble diC8-PIP2, PI(3,5)P2 were purchased from
A.G. Scientific. No significant differences in TRPML1 channel properties were
seen for recordings obtained with full-length diC16 PI(3,5)P2 and diC8 PI(3,5)P2
(ref. 14). For the application of all activators, cytoplasmic (external) solution was
completely exchanged by a solution containing the respective activator. The EC50



































































































































Figure 6 | Rescue effect of MK6-83. (a,b) Effects of 10mM DMSO or MK6-83 on BODIPY FL C5-LacCer trafficking in human patient fibroblasts.
Shown are the representative cells in a. Quantification is shown in b: mean values±s.e.m. of at least 20 cells from three independent experiments;
*Po0.05. Statistical significance was determined via one-way analysis of variance followed by Tukey’s post test. (c) Effects of 10mM DMSO
or MK6-83 on lysosomal zinc accumulation in human patient fibroblasts. (d) Quantification of experiments as shown in c.
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Calcium imaging experiments were performed using fura-2 as described
previously. Briefly, HEK293 cells were plated onto glass coverslips, grown over
night and transiently transfected with the respected cDNAs using TurboFect
transfection reagent (Thermo Scientific). After 24–48 h, cells were loaded for 1 h
with the fluorescent indicator fura-2-AM (4mM; Invitrogen) in a standard bath
solution containing (in mM) 138 NaCl, 6 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES and
5.5 D-glucose (adjusted to pH 7.4 with NaOH). Cells were washed in standard bath
solution for 30 min before measurement. Calcium imaging was performed using a
monochromator-based imaging system (Polychrome IV monochromator, TILL
Photonics).
Lactosylceramide trafficking assay. Human WT, knockout and mutant
TRPML1 fibroblasts were grown in Poly-D-Lysine-coated 1 m–Slide 8 wells (ibidi,
Germany) and were treated for 24 h with DMSO or MK6-83 (in DMSO) at a final
concentration of 10 mM, respectively. Cells were washed with PBS and then
incubated with 5 mM LacCer (BODIPY FL C5-Lactosylceramide (Invitrogen),
prepared according to manufacturer’s instructions) in serum-free DMEM for 1 h at
37 C, in the presence of DMSO or MK6-83. Cells were washed twice with PBS and
then incubated with normal DMEM (with 10% FBS) for 1 h at 37 C. Cells were
washed again with PBS and immediately analysed using a Zeiss Confocal micro-
scope (LSM 510). For data quantification ImageJ software was used. In each
experiment, numbers were calculated based on the total number of vesicles (dots)
per image divided by the number of cells per image. The term ‘cell’ is used instead
of ‘confocal cell section’. Strongly labelled perinuclear regions (marked by dotted
circles) were excluded from vesicle counting.
Zinc imaging. Human WT, knockout and mutant TRPML1 fibroblasts were plated
on 25 mm glass coverslips in six-well plates or grown in Poly-D-Lysine-coated
1 m–Slide 8 wells. After 24–48 h, cells were exposed to 100mM ZnCl2 in DMEM
(with 10% FBS) for 3 h, washed with PBS and incubated with 1 mM FluoZin-3-AM
in PBS for 1 h. Cells were subsequently washed with PBS and incubated for
30–60 min in LysoTracker DeepRed/PBS. Cells were washed again with PBS and
immediately analysed using a Zeiss confocal laser-scanning microscope (LSM 510).
DMSO or MK6-83 were present throughout the experiment. For data quantifica-
tion, ImageJ software was used. In each experiment, numbers were calculated based
on the total number of vesicles (dots) per image divided by the number of cells per
image. The term ‘cell’ is used instead of ’confocal cell section’. The minimum
particle size was set to three pixels.
MTT test for cell viability. The MTT test is based on the reductive conversion of
MTT into formazan crystals by living cells, which determines mitochondrial
activity. Since for most cell populations the total mitochondrial activity is related to
the number of viable cells, this assay is broadly used to measure the in vitro
cytotoxic effects of drugs on cell lines or primary patient cells. HEK293 cells were
maintained in Earle’s Minimum Essential Medium supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 100 U ml 1 penicillin and 100 mg ml 1 strepto-
mycin, trypsinised and seeded in poly-L-lysine-coated 96-well cell culture plates at a
density of 104 cells per well. The following day, medium was exchanged and the test
compounds were added. The cytotoxic compounds plumbagin and staurosporine
(both 1 mM; Sigma-Aldrich, Germany) and DMSO were included as positive and
negative controls, respectively. After 24 h, compounds were removed and cells were
incubated with fresh medium, supplemented with MTT (0.5 mg ml 1) for 3 h.
Subsequently, supernatants were discarded and DMSO was added to lyse the cells
and dissolve formazan crystals. Absorbance at 560 and 670 nm was measured in a
multiwell plate reader (Polarstar Omega, BMG Labtech; Germany). For statistical
analysis, differences of both extinctions were calculated.
Statistical analysis. All error bars are depicted as s.e.m. Statistical significance was
determined via Student’s t-test or one-way analysis of variance followed by Tukey’s
post test. Significance is denoted on figures with asterisks as outlined in the legends.
All data presented are representative of three or more independent experiments.
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